Karen Tkach Tuzman

ARTICLE | Product Development Poised to overhaul PDAC care, RevMed’s longer-term vision spans catalytic inhibition, immune modulation and disease interception By Karen Tkach Tuzman, Director of Biopharma Intelligence With clinical data cementing the value of its tri-complex RAS inhibition platform, RevMed’s story is shifting from whether the platform works to how far the company can extend it.

ARTICLE | Emerging Company Profile The University of Southampton spinout is using its split intein-based platform to disrupt well-characterized but difficult-to-drug targets By Karen Tkach Tuzman, Director of Biopharma Intelligence Having industrialized the cyclic peptide formation and screening methodology its CSO helped pioneer over twenty years ago,  Curve Therapeutics Ltd. is taking on transcription factors and other intracellular targets that have eluded conventional discovery approaches.

ARTICLE | BioCentury Commentary Systems aiming to match tumors to trials need user-centric designs that engage the patient, not just the clinician By Karen Tkach Tuzman, Director of Biopharma Intelligence It happened to me, the way it has doubtlessly happened to so many in our industry. A loved one is diagnosed with an aggressive cancer, and the clock is ticking.